Courtney S P, Williams S, Mansel R E
Department of Surgery, University of Wales College of Medicine, Heat Park, Cardiff, UK.
Int Surg. 1992 Jan-Mar;77(1):55-9.
Monoclonal antibodies 323/A3 and Ca1 have been suggested as markers of breast cancer risk in benign breast disease. We have studied the staining profiles in benign biopsies of 323/A3 and Ca1 in 146 patients. We then compared the staining patterns grouped according to whether the patients were at "high or low" risk of breast cancer by conventional epidemiological or radiological criteria. The results show that the staining profiles are similar between risk groups and that on the risk criteria used in this study 323/A3 and Ca1 will not distinguish patients at risk of developing breast cancer.
单克隆抗体323/A3和Ca1已被认为是良性乳腺疾病中乳腺癌风险的标志物。我们研究了146例患者良性活检中323/A3和Ca1的染色情况。然后,我们根据传统流行病学或放射学标准将患者分为乳腺癌“高风险或低风险”组,比较了两组的染色模式。结果表明,风险组之间的染色情况相似,并且根据本研究使用的风险标准,323/A3和Ca1无法区分有患乳腺癌风险的患者。